Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma

@article{Fujii2017RecentMS,
  title={Recent mass spectrometry-based proteomics for biomarker discovery in lung cancer, COPD, and asthma},
  author={Kiyonaga Fujii and Haruhiko Nakamura and Toshihide Nishimura},
  journal={Expert Review of Proteomics},
  year={2017},
  volume={14},
  pages={373 - 386}
}
ABSTRACT Introduction: Lung cancer and related diseases have been one of the most common causes of deaths worldwide. Genomic-based biomarkers may hardly reflect the underlying dynamic molecular mechanism of functional protein interactions, which is the center of a disease. Recent developments in mass spectrometry (MS) have made it possible to analyze disease-relevant proteins expressed in clinical specimens by proteomic challenges. Areas covered: To understand the molecular mechanisms of lung… 
Quantitative proteomics in lung cancer
TLDR
Both theoretical and practical applications in the use of quantitative proteomics approaches are introduced, with principles of current technologies and methodologies including gel-based, label free, stable isotope labeling as well as targeted proteomics.
Recent insights into human bronchial proteomics – how are we progressing and what is next?
TLDR
The recent achievements and discoveries in human bronchial proteomics are overviewed by outlining how some of the different proteomic techniques/strategies are developed and applied in LC, TB, COPD, and CF and the future roles of bronchia proteomics in predictive proteomics and precision medicine are discussed.
Searching for biomarkers of chronic obstructive pulmonary disease using proteomics: The current state
TLDR
The results in this area published over the past decade show that proteomics indeed has the ability of monitoring alterations in expression profiles of proteins from fluids/tissues of patients affected by COPD and healthy controls, but suggest that it remains a technique mainly generated and developed in research laboratories.
Current status of clinical proteogenomics in lung cancer
TLDR
A large-scale, MS-based, proteomic analysis, together with both NGS-based genomic data and clinicopathological information, will facilitate establishing extensive databases for lung cancer subtypes that can be used for further proteogenomic analyzes.
Current Insights on the Impact of Proteomics in Respiratory Allergies
TLDR
Proteomics has enabled the establishment of several proteins for diagnosing and treating respiratory allergic diseases, and the principal goal of proteomics has been to discover new proteins and use them in precision medicine.
Molecular insights into cancer drug resistance from a proteomics perspective
TLDR
This work reviews the recent advances and challenges in proteomics studies on cancer drug resistance with an emphasis on biomarker discovery, as well as understanding the interconnectivity of proteins in disease-related signaling pathways, and highlights the critical role that post-translational modifications (PTMs) play in the mechanisms of cancerdrug resistance.
Untargeted metabolomics of human plasma reveal lipid markers unique to chronic obstructive pulmonary disease and idiopathic pulmonary fibrosis
TLDR
It is demonstrated that COPD and IPF were characterised by systemic changes in lipid constituents such as essential FA sampled from circulating plasma, and dihydrotestosterone was lower in both diseases.
...
...

References

SHOWING 1-10 OF 112 REFERENCES
Mass spectrometry-based proteomics: the road to lung cancer biomarker discovery.
TLDR
This review describes studies that use mass spectrometry-based proteomics technologies to analyze tumor proteins and peptides, which might represent new diagnostic, prognostic, and predictive markers for lung cancer.
Integrative Proteomics and Tissue Microarray Profiling Indicate the Association between Overexpressed Serum Proteins and Non-Small Cell Lung Cancer
TLDR
The application of extensive peptide level fractionation coupled with label free quantitative proteomics for the discovery of potential serum biomarkers for lung cancer, and the usage of Tissue microarray analysis (TMA) and Multiple reaction monitoring (MRM) assays for the following up validations in the verification phase is described.
Biomarker discovery in asthma and COPD by proteomic approaches
TLDR
This review will report an overview of the current proteomic methods applied to the discovery of candidate biomarkers for asthma and COPD, giving a special emphasis to emerging MS‐based techniques.
Asthma and COPD proteomics: Current approaches and future directions
TLDR
A summary of recent proteomics‐based investigations in the field of asthma/COPD is provided, highlighting major issues related to sampling and processing procedures for proteomic analyses of specific airway and parenchymal specimens.
Analysis of the Plasma Proteome in COPD: Novel Low Abundance Proteins Reflect the Severity of Lung Remodeling
TLDR
In-depth, plasma proteomic analysis identified a group of novel, differentially expressed, low abundance proteins that reflect known pathogenic mechanisms and the severity of lung remodeling in COPD and may also prove useful as COPD biomarkers.
Identification of proteomic signatures associated with lung cancer and COPD.
Proteomic analysis of non-small cell lung cancer tissue interstitial fluids
TLDR
PRDX1 might be correlated with lymph node metastasis and differentiation, and its elevated expression in TIF may be an adverse biomarker for patients with NSCLC.
Proteomic biomarkers in lung cancer
TLDR
The use of different proteomic techniques such as two-dimensional gel electrophoresis, isotope labelling, and mass spectrometry may yield new knowledge on the underlying biology of lung cancer and also allow the development of new early detection tests and the identification of changes in the cancer protein network that are associated with prognosis and drug resistance.
...
...